Cognition Therapeutics (CGTX) Stock Price, News & Analysis

Company Overview

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

Key Stats

• Today's Range: $0.46 to $0.51
• 50-Day Range: $0.40 to $0.61
• 52-Week Range: $0.34 to $2.95
• Volume: 336,050 shs
• Average Volume: 654,864 shs
• Market Capitalization: $19.16 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.00
• Consensus Rating: Moderate Buy

Cognition Therapeutics Stock Analysis - MarketRank™

Cognition Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 417th out of 970 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cognition Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Cognition Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cognition Therapeutics are expected to grow in the coming year, from ($0.96) to ($0.92) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cognition Therapeutics is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cognition Therapeutics is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cognition Therapeutics has a P/B Ratio of 1.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.41% of the float of Cognition Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Cognition Therapeutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cognition Therapeutics has recently increased by 66.23%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cognition Therapeutics does not currently pay a dividend.

Dividend Growth

Cognition Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.41% of the float of Cognition Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Cognition Therapeutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cognition Therapeutics has recently increased by 66.23%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.21

News Sentiment

Cognition Therapeutics has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Cognition Therapeutics this week, compared to 1 article on an average week.

Search Interest

Only 6 people have searched for CGTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

5 people have added Cognition Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cognition Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

20.75% of the stock of Cognition Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

43.35% of the stock of Cognition Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CGTX Stock Analysis - Frequently Asked Questions

How have CGTX shares performed this year?

Cognition Therapeutics' stock was trading at $1.85 on January 1st, 2024. Since then, CGTX shares have decreased by 75.1% and is now trading at $0.4612.
View the best growth stocks for 2024 here.

How were Cognition Therapeutics' earnings last quarter?

Cognition Therapeutics, Inc. (NASDAQ:CGTX) announced its quarterly earnings data on Thursday, August, 8th. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.22) by $0.04.

When did Cognition Therapeutics IPO?

Cognition Therapeutics (CGTX) raised $45 million in an initial public offering (IPO) on Friday, October 8th 2021. The company issued 3,768,116 shares at a price of $11.00-$13.00 per share.

Who are Cognition Therapeutics' major shareholders?

Cognition Therapeutics' top institutional shareholders include Sigma Planning Corp (0.49%). Insiders that own company stock include Lisa Ricciardi, Peggy Wallace and Ellen B Richstone.
View institutional ownership trends.

How do I buy shares of Cognition Therapeutics?

Shares of CGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Cognition Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cognition Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Eli Lilly and Company (LLY), Meta Platforms (META), General Electric (GE), Arista Networks (ANET) and Celestica (CLS).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 11/17/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CGTX
• CUSIP: N/A
• CIK: 1455365
• Web: www.cogrx.com
• Phone: 412-481-2210
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $8.00
• High Stock Price Target: $14.00
• Low Stock Price Target: $1.00
• Potential Upside/Downside: +1,634.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.97)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-25,790,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -150.93%
• Return on Assets: -100.82%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.11
• Quick Ratio: 3.07

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.35 per share
• Price / Book: 1.32

Miscellaneous

• Outstanding Shares: 41,550,000
• Free Float: 32,927,000
• Market Cap: $19.16 million
• Optionable: Not Optionable
• Beta: 1.34